

SRJR LIFESCIENCES LLP

LLPIN: AAR-4517

ILABS CENTRE BUILDING NO.3, NO.18, SOFTWARE UNITS LAYOUT, MADHAPUR,
HYDERABAD, TELANGANA – 500 081

Date: 1st April 2026

To
General Manager
Listing Department
BSE Limited
P J Towers, Dalal Street Fort
Mumbai- 400 001

To
General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

To
Company Secretary
Bafna Pharmaceuticals Ltd
Bafna Towers, 299, Thambu Chetty Street,
Chennai, Tamil Nadu- 600001

Dear Sir,

Sub.: - Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Symbol : BAFNAPH
Security code : 532989
ISIN : INE878I01022


As per Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, SRJR Lifesciences, being the promoter of Bafna Pharmaceuticals Limited ("Company"), hereby declare and confirm that we have not made any encumbrance over the shares held by us in the Company, directly or indirectly, during the financial year ended March 31, 2026.

We request you to take on record the above information and acknowledge the receipt of the same.

Thanking You,

For SRJR Lifesciences LLP


Upendar Mekala Reddy
Designated Partner
DIN:08898174



CC: Audit Committee
Bafna Pharmaceuticals Limited

SRJR LIFESCIENCES LLP

LLPIN: AAR-4517

ILABS CENTRE BUILDING NO.3, NO.18, SOFTWARE UNITS LAYOUT, MADHAPUR,
HYDERABAD, TELANGANA – 500 081

Date: 1st April 2026

To
General Manager
Listing Department
BSE Limited
P J Towers, Dalal Street Fort
Mumbai- 400 001

To
General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

To
Company Secretary
Bafna Pharmaceuticals Ltd
Bafna Towers, 299, Thambu Chetty Street,
Chennai, Tamil Nadu- 600001

Dear Sir,

Sub.: - Disclosure under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Symbol : BAFNAPH
Security code : 532989
ISIN : INE878I01022


As per Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we, SRJR Lifesciences LLP, being the promoter of Bafna Pharmaceuticals Limited ("Company"), hereby declare and confirm that we have not made any encumbrance over the shares held by us in the Company, directly or indirectly, during the financial year ended March 31, 2026.

We request you to take on record the above information and acknowledge the receipt of the same.

Thanking You,

For SRJR Lifesciences LLP

U/R
Kundan M
Upendar Mekala Reddy
Designated Partner
DIN:08898174



CC: Audit Committee
Bafna Pharmaceuticals Limited